source
- Definium Therapeutics reports positive Phase 3 results for oral LSD anxiety drug DT120Definium Therapeutics announced Monday that its experimental oral LSD formulation, DT120, achieved positive outcomes in a Phase 3 trial targeting an anxiety disorder. The trial, the company's thir…
- Definium Therapeutics clinches third phase-3 win for LSD anxiety drug, eyes FDA filingDefinium Therapeutics reported another successful phase 3 trial of its LSD‑based anxiety treatment, DT120 ODT. The Panorama study enrolled 245 patients and compared a 100 µg dose of DT120 with pla…